Novartis reports data from trial of IgA nephropathy treatment
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
IgAN is a heterogeneous, progressive, rare kidney disease and is a major cause of chronic kidney disease worldwide
The offer price corresponds to a premium of 142% on the volume-weighted average price during the last three months
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Empowering Research, Enhancing Proficiency is the theme of this year’s Homoeopathic Symposium
Vericiguat works on a pathway not currently targeted by existing heart failure treatments
Wacker Biotech is a CDMO for the GMP-compliant production of active ingredients for the pharmaceutical industry
Highly effective preservation solutions ensuring the safety and protection of personal care products
Abecma tripled progression-free survival compared to standard regimens in the Phase 3 KarMMa-3 trial
Subscribe To Our Newsletter & Stay Updated